Company / R&D Expense
Atai Beckley N.V. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$900.0K
FY2025
5-year range
$400.0K / $48.0M
FY2021-FY2025
Trend
+125.0%
vs FY2024
Sector context
#208 of 210
Health Care
What the data says
Among 210 Health Care companies, Atai Beckley N.V. is in the bottom 1% for r&d expense. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $900,000.
Based on SEC 10-K filings.
$900,000 in FY2025 with a 5-year CAGR of -39.8%.
Declined from $2M to $900,000 over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -31.5%
- 5-Year CAGR
- -39.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 210This company $900.0K Sector average $644.0M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -39.8%, indicating a declining trend.
- In FY2025, r&d expense increased 125.0% year-over-year.
- Ranks #208 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $900.0K | +125.0% |
| FY2024 | $400.0K | -80.0% |
| FY2023 | $2.0M | -28.6% |
| FY2022 | $2.8M | -94.2% |
| FY2021 | $48.0M | +320.4% |
| FY2020 | $11.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026